Table 3 Risk associated with study drug compared to placebo for adverse events in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trials
From: Class effects of SGLT2 inhibitors on cardiorenal outcomes
DECLARE-TIMI 58 | CANVAS | EMPA–REG OUTCOME | CREDENCE | |
|---|---|---|---|---|
Male genital infectiona | +b | +b | +b | +b |
Female genital infectiona | +b | +b | + | |
Any AE | N/A | N/A | −b | −b |
Serious AE | −b | −b | −b | −b |
AE causing discontinuation | +b | + | −b | N/A |
Hypoglycemia | −b | + | − | − |
UTI | − | + | − | + |
Fracture | + | +b | − | − |
Hyperkalemia | N/A | + | N/A | − |
Amputation | + | +b | N/A | + |
AKI | −b | − | −b | − |
Breast cancer | 0 | + | N/A | + |
Bladder cancer | −b | − | N/A | + |
DKA | +b | + | + | +b |